Gilead Sciences, Inc. (NASDAQ:GILD) is considered one of the most undervalued NASDAQ stocks to buy now. Moody’s upgraded Gilead’s outlook to positive, citing momentum in its product pipeline, introducing Yeztugo, an HIV prevention injectable.

Moody’s also highlighted Gilead’s strong position in liver and cancer treatment platforms with drugs like Livdelzi and Trodelvy. Governance risk concerns were addressed, praising management’s financial strategy and credibility.

Gilead Sciences, Inc. (NASDAQ:GILD) is a U.S. biopharmaceutical company focusing on antiviral treatments for various illnesses, including COVID-19, hepatitis, influenza, and HIV/AIDS. The company is headquartered in Foster City, California.

While GILD shows investment potential, other AI stocks may offer greater upside with lower risk. Investors seeking undervalued AI stock can explore options benefiting from Trump-era tariffs and onshoring trends.

Explore top Magic Formula Stocks for 2025 and Retirement Stocks according to Hedge Funds for more investment insights. This article is originally published on Insider Monkey.

Read more at Yahoo Finance: Gilead Sciences (GILD) Stock Sees Positive Outlook Amid HIV, Liver, and Cancer Drug Momentum